Literature DB >> 12054166

Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism.

Suzanne M Jan De Beur1, Richard B Finnegan, John Vassiliadis, Brian Cook, Dana Barberio, Scott Estes, Partha Manavalan, Joseph Petroziello, Stephen L Madden, Justin Y Cho, Rajiv Kumar, Michael A Levine, Susan C Schiavi.   

Abstract

Oncogenic osteomalacia (OOM) is associated with primitive mesenchymal tumors that secrete phosphaturic factors resulting in low serum concentrations of phosphate and calcitriol, phosphaturia, and defective bone mineralization. To identify overexpressed genes in these tumors, we compared gene expression profiles of tumors resected from patients with OOM and histologically similar control tumors using serial analysis of gene expression (SAGE). Three hundred and sixty-four genes were expressed at least twofold greater in OOM tumors compared with control tumors. A subset of 67 highly expressed genes underwent validation with an extended set of OOM and control tumors using array analysis or reverse-transcription polymerase chain reaction (RT-PCR). Ten of these validated genes were consistently overexpressed in all OOM tumors relative to control tumors. Strikingly, genes with roles in bone matrix formation, mineral ion transport, and bone mineralization were highly expressed in the OOM tumors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12054166     DOI: 10.1359/jbmr.2002.17.6.1102

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  58 in total

1.  Evidence for a bone-kidney axis regulating phosphate homeostasis.

Authors:  L Darryl Quarles
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

2.  Tumor-Induced Osteomalacia.

Authors:  Rajiv Kumar; Andrew L Folpe; Brian P Mullan
Journal:  Transl Endocrinol Metab       Date:  2015

3.  Secreted frizzled-related protein-4 reduces sodium-phosphate co-transporter abundance and activity in proximal tubule cells.

Authors:  Theresa J Berndt; Bernhard Bielesz; Theodore A Craig; Peter J Tebben; Desa Bacic; Carsten A Wagner; Stephen O'Brien; Susan Schiavi; Jurg Biber; Heini Murer; Rajiv Kumar
Journal:  Pflugers Arch       Date:  2005-09-09       Impact factor: 3.657

Review 4.  Recent advances in renal phosphate handling.

Authors:  Emily G Farrow; Kenneth E White
Journal:  Nat Rev Nephrol       Date:  2010-02-23       Impact factor: 28.314

Review 5.  Lymphatic vessels are present in phosphaturic mesenchymal tumours.

Authors:  K Williams; A Flanagan; A Folpe; R Thakker; N A Athanasou
Journal:  Virchows Arch       Date:  2007-08-03       Impact factor: 4.064

6.  Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men.

Authors:  Sherri-Ann M Burnett-Bowie; Natalia Mendoza; Benjamin Z Leder
Journal:  Bone       Date:  2006-12-08       Impact factor: 4.398

Review 7.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

Review 8.  Role of prostaglandins in the pathogenesis of X-linked hypophosphatemia.

Authors:  Michel Baum; Ashu Syal; Raymond Quigley; Mouin Seikaly
Journal:  Pediatr Nephrol       Date:  2006-05-24       Impact factor: 3.714

9.  Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.

Authors:  Despina Sitara; Mohammed S Razzaque; Martina Hesse; Subbiah Yoganathan; Takashi Taguchi; Reinhold G Erben; Harald Jüppner; Beate Lanske
Journal:  Matrix Biol       Date:  2004-11       Impact factor: 11.583

Review 10.  Do osteocytes contribute to phosphate homeostasis?

Authors:  Jian Q Feng; Ling Ye; Susan Schiavi
Journal:  Curr Opin Nephrol Hypertens       Date:  2009-07       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.